- Home
- BLCO vs LEGN Comparison
BLCO vs LEGN Comparison
Compare BLCO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLCO
- LEGN
- Stock Information
- Founded
- BLCO 1853
- LEGN 2014
- Country
- BLCO Canada
- LEGN United States
- Employees
- BLCO N/A
- LEGN N/A
- Industry
- BLCO Ophthalmic Goods
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- BLCO Health Care
- LEGN Health Care
- Exchange
- BLCO Nasdaq
- LEGN Nasdaq
- Market Cap
- BLCO 4.9B
- LEGN 5.4B
- IPO Year
- BLCO 2022
- LEGN 2020
- Fundamental
- Price
- BLCO $13.72
- LEGN $39.59
- Analyst Decision
- BLCO Hold
- LEGN Strong Buy
- Analyst Count
- BLCO 13
- LEGN 12
- Target Price
- BLCO $15.83
- LEGN $73.91
- AVG Volume (30 Days)
- BLCO 758.1K
- LEGN 1.5M
- Earning Date
- BLCO 07-30-2025
- LEGN 08-08-2025
- Dividend Yield
- BLCO N/A
- LEGN N/A
- EPS Growth
- BLCO N/A
- LEGN N/A
- EPS
- BLCO N/A
- LEGN N/A
- Revenue
- BLCO $4,829,000,000.00
- LEGN $728,303,000.00
- Revenue This Year
- BLCO $6.97
- LEGN $65.33
- Revenue Next Year
- BLCO $5.48
- LEGN $54.68
- P/E Ratio
- BLCO N/A
- LEGN N/A
- Revenue Growth
- BLCO 11.94
- LEGN 112.46
- 52 Week Low
- BLCO $10.45
- LEGN $27.34
- 52 Week High
- BLCO $21.69
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- BLCO 63.37
- LEGN 68.12
- Support Level
- BLCO $12.02
- LEGN $38.86
- Resistance Level
- BLCO $14.35
- LEGN $40.78
- Average True Range (ATR)
- BLCO 0.45
- LEGN 1.52
- MACD
- BLCO 0.06
- LEGN 0.33
- Stochastic Oscillator
- BLCO 72.96
- LEGN 85.77
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.